NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

FDA Grants Breakthrough Status to Vision-Saving Drug for Optic Neuritis

Oculis (OCS) receives FDA Breakthrough Therapy Designation for Privosegtor, a promising treatment that could become the first neuroprotective therapy for optic neuritis and related eye conditions.

FDA Grants Breakthrough Status to Vision-Saving Drug for Optic Neuritis
Credit: Oculis
Already have an account? Sign in.
01/06/2026 · 10:49 AM
OCS
/ Don’t stop at just one post.

Related↓

Oculis DIAMOND Trial Results: Vision Goal Not Met, But Retina Improved – Company Shifts Focus
05/29/2026 · 4:17 PM

Oculis DIAMOND Trial Results: Vision Goal Not Met, But Retina Improved – Company Shifts Focus

Oculis eye drops failed main vision goal in DME trials but reduced swelling; no FDA filing, company shifts focus, strong cash until 2029.

/ Subscriber only
/ Read more

Feed↓

Sidus Space Strengthens Cash Position but Posts Lower Revenue and Higher Cash Burn in Q2 2026
08/14/2026 · 5:31 PM

Sidus Space Strengthens Cash Position but Posts Lower Revenue and Higher Cash Burn in Q2 2026

Sidus Space reported Q2 2026 revenue of $583,000 (−54% YoY) due to contract timing, a $5.1M adjusted EBITDA loss, $166.5M cash, and key LizzieSat milestones.

/ Subscriber only
Diana Shipping Ends Nine-Month Pursuit of Genco Amid Valuation Standoff
08/14/2026 · 5:06 PM

Diana Shipping Ends Nine-Month Pursuit of Genco Amid Valuation Standoff

Diana Shipping walks away from Genco deal as board demands a 57% premium and nearly half the combined company.

/ Subscriber only
PayPal Weighs Higher Offer from Stripe and Advent International
Featured/ 08/14/2026 · 4:09 PM

PayPal Weighs Higher Offer from Stripe and Advent International

Stripe & Advent may raise their $53B+ bid for PayPal. Negotiations continue—no deal finalized amid valuation and regulatory concerns.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe